|24th September 2020||David N Gill||8,000||Open or private purchase||$2.13||$17,040.00|
|18th September 2020||Associates, L.L.C. Cdk||6,000||Open or private purchase||$2.20||$13,200.00|
|17th September 2020||Associates, L.L.C. Cdk||1,473,377||Open or private purchase||$2.25||$3,315,098.25|
|15th September 2020||Matthew Pauls||227,272||Grant/award etc.||$0.00|
|3rd September 2020||David N Gill||23,104||Payment by withholding||$3.61||$83,405.44|
|13th August 2020||A Brian Davis||7,900||Open or private purchase||$6.24||$49,296.00|
|6th July 2020||Jeffrey W Sherman||9,100||Open or private sale||$57.50||$523,250.00|
|2nd July 2020||John Johnson||315,000||Grant/award etc.||$0.00|
|2nd July 2020||John Johnson||13,194||Sale back to the issuer||$18.00||$237,492.00|
|2nd July 2020||John Johnson||7,281||Sale back to the issuer||$18.00||$131,058.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 7/10.
Strongbridge Biopharma Plc operates as a commercial-stage biopharmaceutical company. The company focuses on the development and commercialization of therapies for rare diseases. Its pipeline is comprised of Keveyis, Macrilen, Recorlev, and Veldoreotide.